Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Helix BioPharmaHBPCF 28 Cash-to-Debt is 7.92 as of Apr. 2026, which is 100% below its 10-year median of 10,000.00. GuruFocus rates HBPCF with a GF Score™ of 28/100. Among 1,355 Biotechnology companies, Helix BioPharma ranks better than 51.07% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Helix BioPharma's cash to debt ratio for the quarter that ended in Apr. 2026 was 7.92.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Helix BioPharmacould pay off its debt using the cash in hand for the quarter that ended in Apr. 2026.
The historical rank and industry rank for Helix BioPharma's Cash-to-Debt or its related term are showing as below:
HBPCF'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.09 Med: No Debt Max: No Debt
Current: 7.92
During the past 13 years, Helix BioPharma's highest Cash to Debt Ratio was No Debt. The lowest was 0.09. And the median was No Debt.
HBPCF's Cash-to-Debt is ranked better than 51.07% of 1355
companies
in the Biotechnology industry
Industry Median: 7.29
vs HBPCF: 7.92
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Helix BioPharma Cash-to-Debt Related Terms
Helix BioPharma Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Helix BioPharma's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
HBPCF vs VRTX, REGN, RVMD: Cash-to-Debt Comparison
For the Biotechnology subindustry, Helix BioPharma's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Helix BioPharma Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Helix BioPharma's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Helix BioPharma's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Helix BioPharma (HBPCF) has a Cash-to-Debt of 7.92 as of Apr. 2026. This is 100% below median its historical median of 10,000.00. Over the past decade, Helix BioPharma's Cash-to-Debt has ranged from 0.09 to 10,000.00. According to the industry distribution chart, Helix BioPharma ranks #663 out of 1355 companies in the Biotechnology industry, placing it in the top 48.9%.
Is Helix BioPharma's Cash-to-Debt too high?
Helix BioPharma's current Cash-to-Debt of 7.92 is 100% below median its 10-year median of 10,000.00. Over the past 10 years, this metric has ranged from a low of 0.09 to a high of 10,000.00. The Biotechnology industry median Cash-to-Debt is 7.29. Helix BioPharma's value of 7.92 is 8.6% above this industry median. Based on the distribution chart, Helix BioPharma ranks #663 out of 1355 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Helix BioPharma has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Helix BioPharma's Cash-to-Debt compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Helix BioPharma ranks #663 out of 1355 companies for Cash-to-Debt. This puts Helix BioPharma in the upper half of its industry. The industry median Cash-to-Debt is 7.29. Helix BioPharma's value of 7.92 is 8.6% above this benchmark. Historically, Helix BioPharma's own Cash-to-Debt has ranged from 0.09 to 10,000.00 over the past decade. While the company's 10-year median is 10,000.00 vs. the industry median of 7.29, Helix BioPharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 7.29, based on 1,355 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Helix BioPharma's current Cash-to-Debt of 7.92 is 8.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 7.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Helix BioPharma's current Cash-to-Debt is 7.92, which is 100% below median its own 10-year median of 10,000.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Helix BioPharma stock overvalued right now?
Helix BioPharma (HBPCF) has a current Cash-to-Debt of 7.92. The current Cash-to-Debt is 7.92, which is 100% below median its 10-year median of 10,000.00 and 8.6% above the Biotechnology industry median of 7.29. Helix BioPharma's overall GF Score™ is 28/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Helix BioPharma (HBPCF), the current Cash-to-Debt is 7.92 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Helix BioPharma Corp is a clinical-stage biopharmaceutical company developing therapies in immune-oncology focused on cancer prevention and treatment. The Company is developing a proprietary platform of bio-conjugates targeting hard-to-treat solid tumors over-expressing CEACAM6, including Tumor Defense Breaker, L-DOS47, and three CEACAM6-specific antibody-drug conjugates. Its pre-IND candidates include LEUMUNA, an oral immune checkpoint modulator for hematological malignancies, and GEMCEDA, an oral prodrug of gemcitabine for solid tumors.
28GF Score
Get the complete analysis for HBPCF
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HBPCF has been successfully added to your 
